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Abstract  
BACKGROUND: Growing evidence supports the notion that the onset of tumorigenesis could occur 
through cancer stem cells (CSCs). These tumour cells show low proliferative rates, high self-
renewal capacity, propensity to differentiate into active proliferating tumour cells & resistance to 
chemoradiotherapy thus, possibly causing local recurrences & metastasis formation. CD44 has 
been used as a marker to isolate CSCs from colorectal carcinoma (CRC).  
AIM: To investigate the immunohistochemical expression of cancer stem cells marker (CD44) in 
CRC and correlate its expression with the clinicopathological aspects, TNM staging and modified 
Dukes’ classification.  
MATERIALS AND METHODS: Tumour biopsies from colectomy specimens of 60 patients with 
CRC were stained with hematoxylin-eosin for histological evaluation then immunostained with 
monoclonal antibodies against CD44 which was detected in term of negative or positive expression.  
RESULTS: CD44 was demonstrated in 58.3% (35/60) of cases and showed statistically significant 
correlation with tumour site and histological type (p-value < 0.05). However, CD44 showed 
statistically insignificant inverse correlation with tumour invasiveness (T), lymph node status (N), 
grade, TNM stage grouping and modified Dukes’ classification, while it was directly correlated with 
distant metastasis (M) (p-value > 0.05). Chi-square /Fisher exact test proportion independence and 
the p-value are set significant at 0.05 level.  
CONCLUSION: the CD44 rate of expression is higher in the colon than rectum and in 
adenocarcinoma than mucinous and undifferentiated carcinoma. CD44 showed statistically 
insignificant relation with T, N, M, grade, TNM stage grouping and modified Dukes’ classification. 
 
 
 
 
 
Introduction 
 
Colorectal cancer (CRC) is the third most 
common type of cancer [1]. Although the median 
overall survival of patients with metastatic colorectal 
cancer has increased from 12 months to 
approximately 24 months over the past decade as a 
result of an improvement in systemic therapies 
including new chemotherapeutic agents, the 5-year 
survival is still pessimistic [2].  
A growing body of evidence supports the 
notion that only a small subset of cells within a solid 
tumour has 'stem-like' characteristics. These tumor-
initiating cells, or cancer stem cells (CSCs), distinct 
from non-malignant stem cells, show low proliferative 
rates, high self-renewal capacity, propensity to 
differentiate into active proliferating tumour cells, and 
resistance to chemotherapy or radiation [3]. Notably, 
owing to their high expression of DNA repair 
mechanisms, detoxifying enzymes, such as aldehyde 
dehydrogenase-1 (ALDH1), and molecular pumps, 
CSCs might survive radiochemotherapy; thus, 
possibly causing local recurrences and metastasis 
formation despite treatment [4]. 
Despite the potentially high clinical relevance 
of CSCs, little is known about the prognostic value of 
the expression of putative CSC markers in colorectal 
cancers. Contradictory findings have been reported 
about the association between the expression of 
CD44 and tumour progression [5]. 
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Material and Methods 
 
 A total of 60 stored, formalin fixed, paraffin 
embedded tumour biopsies from colectomy 
specimens of patients with colorectal cancer were 
collected from Kasr El Aini Hospital and multiple 
private laboratories with the permission of the head of 
these labs, the specimens were anonymous for 
confidentiality and replaced by numbers. 
The site of the tumour was classified into the 
right colon (cecum, ascending colon, hepatic flexure 
and transverse colon), left colon (splenic flexure, 
descending colon and sigmoid) and rectum, while the 
size of the tumour was calculated as the length of the 
largest diameter. Size and site, as well as age and 
sex, were obtained from the pathology reports of the 
patients. Undifferentiated carcinoma cases were 
documented immunohistochemically from where the 
cases were recruited. 
The tumour extension into other organs, 
distant metastasis if present and the lymph node 
status were also obtained from the diagnosis present 
in the pathology reports (clinical data of distant 
metastasis in other organs were also obtained from 
the patient’s sheet). 
The paraffin blocks of the tumour were serially 
sectioned at 4 μm thickness. Afterwards, they were 
stained with routine hematoxylin-eosin stain for 
pathological examination and morphologic 
classification of the colorectal cancer according to the 
recommendations of the World Health Organization 
[6] including histological types, subtypes, tumor grade, 
depth of tumor invasion, perineural invasion and 
lymphovascular emboli while staging was performed 
using modified Dukes’ classification of the disease [7], 
and TNM staging system [8] for each case. 
Paraffin section from each case was 
processed for immunostaining using CD44 Std. / 
HCAM AB-4 (0.7 ml. of antibody prediluted 0.05 mol/L 
Tris-HCl, pH 7.6 containing stabilising protein and 
0.015 mol/L sodium azide – Thermo Fisher Scientific. 
UK) and Econo Tek HRP Anti-Polyvalent (DAP) 
ready-to-use (Scy Tek Laboratories inc. USA) 
detection system. 
CD44 stained sections were examined at high 
power for immunohistochemical expression and were 
divided into negative (no immunoreactivity in any 
cells) and positive (membrane and/or cytoplasm 
immunoreactivity present) [9]. 
The antibody labels approximately 90% of all 
lymphocytes, both T cells and B cells [10], were 
positively stained lymphocytes were used as an 
internal positive control. 
In colorectal cancer, metastasis was almost 
exclusively a property of the CSCs that exhibited long-
term self-renewing capacity [11]. So we used to divide 
the histological types, tumour grade and invasiveness 
(T) into metastatic and non-metastatic groups to 
correlate them with the rate of CD44 expression. 
 
Statistical methods 
SPSS version 18.0 was used for data 
management. Mean and standard deviation described 
quantitative data and non-parametric t-test compared 
two independent groups and non-parametric ANOVA 
compared more than two groups. Chi-square /Fisher 
exact test proportion independence and the p-value 
are set significant at 0.05 level. 
 
 
Results 
 
The characteristics of the study population are 
shown in Table 1. The subjects consisted of 29 males 
(48.3%) and 31 females (51.7%), with a mean age of 
54.86 years (median, 56 years; range, 25–75 years) 
and a mean tumour size of 6.25 cm (median, 6 cm; 
range, 2–16 cm). Most of the cases were 
adenocarcinoma (75%) followed by mucinous 
carcinoma (21.7%) and undifferentiated carcinoma 
(3.3%). The tumour was distributed regarding the site; 
(75%) in the colon while (25%) of the cases were 
found in the rectum. The TNM staging is applied 
according to the American Joint Committee on Cancer 
(AJCC) and the International Union for Cancer Control 
(UICC) where it encodes the extent of the primary 
tumor (T), regional lymph nodes (N), and distant 
metastases (M) 3, 17, 31, and 9 patients had stage I–
IV cancers, respectively [8]. According to Modified 
Dukes’ classification [7] cases in this study are 
classified into 20 cases (33.3%) B, 31 cases (51.7%) 
stage C and 9 cases (15%) stage D with no cases of 
stage A.  
Expression of CD44s in primary tumour was 
demonstrated in 58.3% (35/60). The relationships 
between tumour CD44s expression and the 
clinicopathological features of CRC are summarised in 
Table 1. 
The characteristics of the study population are 
shown in Table 1. The subjects consisted of 29 males 
(48.3%) and 31 females (51.7%), with a mean age of 
54.86 years (median, 56 years; range, 25–75 years) 
and a mean tumour size of 6.25 cm (median, 6 cm; 
range, 2–16 cm). Most of the cases were 
adenocarcinoma (75%) followed by mucinous 
carcinoma (21.7%) and undifferentiated carcinoma 
(3.3%). The tumour was distributed regarding the site; 
(75%) in the colon while (25%) of the cases were 
found in the rectum. The TNM staging is applied 
according to the American Joint Committee on Cancer 
(AJCC) and the International Union for Cancer Control 
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(UICC) where it encodes the extent of the primary 
tumor (T), regional lymph nodes (N), and distant 
metastases (M) 3, 17, 31, and 9 patients had stage I–
IV cancers, respectively [8].  
Table 1: Description of set of patients and CD44 rate of 
expression in the study 
 
No. (%) 
CD44 expression P-
value +ve no. (%) -ve no. (%) 
Patients 60 25 (41.7%) 35 (58.3%)  
Gender: 
Male 
Female 
 
29 (48.3%) 
31 (51.7%) 
 
16 (55.2%) 
19 (61.3%) 
 
13 (4.48%) 
12 (38.7%) 
0.63 
Age: 
Range 
Mean  
Std. deviation 
 
25-75 yrs 
54.867 
11.0415 
 
 
57.086 
8.8695 
 
 
51.760 
13.0776 
0.07 
Tumour site: 
Colon 
Rectum 
 
45 (75%) 
15 (25%) 
 
30 (66.7%) 
5 (33.3%) 
 
15 (33.3%) 
10 (66.7%) 
0.02* 
Tumour size: 
Range 
Mean 
Std. deviation 
 
2-16 cm. 
6.250 
2.5669 
 
 
5.929 
2.1287 
 
 
6.700 
3.0687 
0.29 
Histological type: 
Adenocarcinoma 
Mucinous 
Undifferentiated  
 
45 (75%) 
13 (21.7%) 
2 (3.3%) 
 
31 (68.9%) 
4 (30.8%) 
0 (0%) 
 
14 (31.1%) 
9 (69.2%) 
2 (100%) 
0.01* 
Adenocarcinoma: ** 
Metastatic 
Non metastatic  
45 (75%) 
8 
37 
31 (68.9%) 
6 (75%) 
25 (67.6%) 
14 (31.1%) 
2 (25%) 
12 (32.4%) 
1.0 
Mucinous: ** 
Metastatic 
Non metastatic 
13 (21.7%) 
1 
12 
4 (30.8%) 
1 (100%) 
3 (25%) 
9 (69.2%) 
0 (0%) 
9 (75%) 
0.38 
Tumor grade: ** 
Grade 1 
Grade 2 
Grade 3 
 
0 (0%) 
53 (83.3%) 
7 (11.7%) 
 
0 (0%) 
33 (62.3%) 
2 (28.6%) 
 
0 (0%) 
20 (37.7%) 
5 (71.4%) 
0.10 
Grade 2: ** 
Metastatic 
Non metastatic 
53 (83.3%) 
8 
45 
33 (62.3%) 
6 (75%) 
27 (60%) 
20 (37.7%) 
2 (25%) 
18 (40%) 
0.7 
Grade 3: ** 
Metastatic 
Non metastatic 
7 (11.7%) 
1 
6 
2 (28.6%) 
1 (100%) 
1 (16.7%) 
5 (71.4%) 
0 (0%) 
5 (83.3%) 
0.29 
Tumor extent (T):  
0.52 
T1 
T2 
T1+T2 
1 (1.7%) 
8 (13.3%) 
7 (77.8%) 2 (22.2%) 
T3 T3 45 (75%) 25 (55.6%) 20 (44.4%) 
T4a 
T4b 
T4a+T4b 
3 (5%) 
3 (5%) 
3 (50%) 3 (50%) 
T1+T2: ** 
Metastatic 
Non metastatic 
9 (15%) 
1 
8 
7 (77.8%) 
1 (100%) 
6 (75%) 
2 (22.2%) 
0 (0%) 
2 (25%) 
1.0 
T3: ** 
Metastatic 
Non metastatic 
45 (75%) 
5 
40 
25 (55.6%) 
4 (80%) 
21 (52.5%) 
20 (44.4%) 
1 (20%) 
19 (47.5%) 
0.36 
T4a+T4b: * 
Metastatic 
Non metastatic 
6 (10%) 
3 
3 
3 (50%) 
2 (66.7%) 
1 (33.3%) 
3 (50%) 
1 (33.3%) 
2 (66.7%) 
1.0 
Lymph node status 
(N): 
N0 
N1a 
N1b 
N2a 
N2b 
 
0.55 
N0 22 (36.7%) 15 (68.2%) 7 (31.8%) 
N1a+N1b 
15 (25%) 
5 (8.3%) 
12 (60%) 8 (40%) 
N2a+N2b 
11 (18.3 %) 
7 (11.7%) 8 (44.4%) 10 (55.6%) 
Distant metastasis (M): 
M0 
M1a 
M1b 
 
0.72 
51 (85%) 29 (56.9%) 22 (43.1%) 
4 (6.7%) 
5 (8.3%) 
6 (75%) 3 (25%) 
Stage grouping: 
I 
II 
III 
IV 
 
3 (5%) 
17 (28.4%) 
31 (51.6%) 
9 (15%) 
 
2 (66.7%) 
11 (64.7%) 
16 (51.6%) 
6 (66.7%) 
 
1 (33.3%) 
6 (35.3%) 
15 (48.4%) 
3 (33.3%) 
0.78 
Modified Dukes’: 
Stage A 
Stage B 
Stage C 
Stage D 
 
0 (0%) 
20 (33.3%) 
31 (51.7%) 
9 (15%) 
 
0 (0%) 
13 (65%) 
16 (49.6%) 
6 (66.7%) 
 
0 (0%) 
7 (35%) 
15 (50.4%) 
3 (33.3%) 
0.55 
Perineural invasion: 
Absent 
Present 
 
52 (86.7%) 
8 (13.3%) 
 
Lympho-vascular emboli: 
Absent 
Present 
 
58 (96.7%) 
2 (3.3%) 
(*) statistically significant p-value; (**) pathological parameters such as the grade, 
histological types and invasiveness (T) of the tumour were classified into metastatic and 
non-metastatic groups, the metastatic groups showed a higher rate of CD44 expression 
than non-metastatic ones. 
 
According to Modified Dukes’ classification [7] 
cases in this study are classified into 20 cases 
(33.3%) B, 31 cases (51.7%) stage C and 9 cases 
(15%) stage D with no cases of stage A. 
Expression of CD44s in primary tumour was 
demonstrated in 58.3% (35/60). The relationship 
between tumour CD44s expression and the 
clinicopathological features of CRC is summarised in 
Table 1. 
 
Figure 1: Adenocarcinoma GII with strong CD44 expression; 
membranous and focal cytoplasmic staining (x400) 
 
CD44 showed a higher rate of expression in 
colon rather than rectal cases (p-value 0.02) and a 
higher rate of expression in adenocarcinoma cases 
than mucinous and undifferentiated carcinoma cases 
(p-value 0.01). The correlation was statistically 
significant by Chi-square /Fisher exact test proportion 
independence (p-value is set significant at 0.05 level). 
 
Figure 2: Mucinous carcinoma GII with strong CD44 expression and 
evident lymphocyte staining as internal control (x100) 
 
The CD44 rate of expression showed 
statistically insignificant correlation with distant 
metastasis (M) and the metastatic group of all 
parameters including grade, histological types and 
invasiveness. Whereas it showed statistically 
insignificant inverse correlation with the grade, 
invasiveness (T), lymph node status (N), TNM stage 
grouping and modified Dukes’ staging (except for 
stage IV and stage D respectively which represent the 
metastatic stage) (p-value > 0.05). 
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Figure 3: Undifferentiated carcinoma showing negative CD44 
expression with focal staining of the lymphocytes which acts as 
internal control (x400) 
 
No association was detected between CD44 
expression and age, gender, tumour size, perineural 
invasion or lymphovascular invasion (p-value > 0.05). 
 
 
Discussion 
 
Cancer-related death from colorectal cancer 
is usually due to the development of distant 
metastasis. Approximately 70% of all patients 
diagnosed with CRC undergo potentially curative 
surgery, but half of those present with or develop 
advanced local disease or metastases [12]. Although 
several prognostic factors exist, including clinical 
staging classification, a more specific recognition 
marker for CRC with high metastatic potential would 
provide useful information for evaluating adjuvant 
therapies [13]. 
The concept of the contribution of colorectal cancer 
stem cells to tumour development is widely accepted, 
but the relation of individual CSC markers expression 
to disease prognosis is still not completely clear [14]. 
The relation between the site of the primary 
tumor and the rate of CD44 expression was 
statistically significant, where rectal tumors showed 
lower rate of CD44 expression (33.3%) than colonic 
tumors (66.7%) with slightly higher rate of expression 
in the right colon (70.8%) than in the left colon 
(61.9%) which is consistent with the results of [15] 
who found lower rate of CD44 expression in rectum 
(44.4%) than colon (64.4%). However, other studies 
showed higher rate of CD44 expression in rectum 
(48%) than colon (21.2%) [16], rectum (53.8%) and 
colon (30.8%) [13] and in rectum and left colon 
(53.8%) each then right colon (45.2%) (Al-Maghraby 
et al., 2012) [17]. 
The rate of CD44 expression varied according 
to histological type where there was statistically 
significant correlation between the rate of CD44 
expression and the histological type. Adenocarcinoma 
cases showed the highest rate of CD44 expression 
(68.9%), followed by mucinous carcinoma (30.8%) 
then undifferentiated carcinoma which showed no 
CD44 expression. While other studies found a higher 
rate of CD44 expression in mucinous carcinoma 
(61.1%) than adenocarcinoma (49.5%) [18] and also 
higher in mucinous carcinoma (85.7%) than 
adenocarcinoma (55.9%) [15]. 
The role of CD44 as CSC marker itself is 
under debate, where Liu et al. (2014) [19] stated that 
CD44 is of functional importance for cancer initiation, 
progression, maintenance of the properties of CSC. 
While Pitule et al. (2014)  [14] suggested that the use 
of CD44 as a single prognostic marker of CRC 
behaviour is impossible. Moreover Galizia et al. 
(2012) [20] results showed that evaluation of 
combined CD133/CD44 expression could be useful to 
identify putative colorectal CSCs than CD133 and 
CD44 individually which failed to identify colorectal 
CSCs.  
The inconsistency and controversy of results 
from various studies correlating CD44 
immunoexpression in relation to clinicopathological 
parameters may be related to technical factors, such 
as the type of antibody, differences in immunostaining 
method, type of tissue blocks, immunostaining scoring 
method and the cut-off for negative/positive or 
low/high [17]. 
We can also suggest another cause of 
controversy of results; which is the different functions 
of CD44 that may be presented in some tumours and 
absent in others. This suggestion is supported by 
Gunthert (1996) [21] who mentioned that during the 
malignant transformation process, and depending on 
the origin, the cell either gains or loses its ability to 
express some forms of this adhesion molecule. Thus, 
in human malignancies, it seems that the staining 
pattern for CD44 isoforms differs between the different 
tumour types, supporting the concept that the growth 
advantage for cancer cells contributed by CD44 
depends on the cellular background. 
A limitation of this study was the small scale 
of cases and unspecified selection of single parameter 
such as; studying CD44 expression in relation to 
recurrent cases, certain histological type, grade or 
stage (whether of invasiveness, lymph node status or 
metastasis) or even in relation to age, sex or site 
individually. 
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